Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
Rhea-AI Summary
Amneal (Nasdaq: AMRX) announced that Co-Chief Executive and President Chirag Patel will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 in Miami, FL. The company presentation is scheduled for Tuesday, June 9, 2026, at 8:40 AM EDT.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – AMRX
On the day this news was published, AMRX declined 2.05%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Positive | -3.8% | Reported Q1 2026 results and affirmed raised full-year guidance. |
| Apr 22 | Acquisition announcement | Positive | +1.1% | Agreed to acquire Kashiv BioSciences to build biosimilars platform. |
| Apr 22 | Acquisition & earnings | Positive | +1.1% | Detailed Kashiv acquisition terms plus strong preliminary Q1 results. |
| Apr 20 | Clinical trial update | Positive | -4.7% | Positive interim Phase 4 ELEVATE-PD data for CREXONT in Parkinson’s. |
| Apr 14 | Product launch | Positive | +2.3% | Launched first two U.S. respiratory MDI generics with sizeable markets. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive operational and clinical news has sometimes seen mixed share price reactions, with both gains and selloffs following favorable updates.
Over the last few months, Amneal reported strong Q1 2026 results with net revenue of $723M and raised FY2026 guidance, while shares fell 3.79% the next day. It announced a planned acquisition of Kashiv BioSciences, targeting a global biosimilars platform, paired with preliminary Q1 strength, which saw a 1.08% gain. Positive Phase 4 CREXONT data for Parkinson’s disease led to a 4.67% decline, while the U.S. launch of two inhalation generics coincided with a 2.26% rise. Today’s conference participation fits into this steady stream of corporate developments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will participate and present at Goldman Sachs 47th Annual Global Healthcare Conference 2026 being held on June 8-10 at the Loews Miami Beach Hotel in Miami, FL.
A company presentation will take place on Tuesday June 9, 2026, at 8:40AM EDT. A live webcast of the presentation will be available here.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.
Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
Media Contact
Brandon Skop
Sr. Director, Corporate Communications
brandon.skop@amneal.com
